Promising combo for aplastic anemia trial pulled before start

NCT ID NCT06424639

Terminated Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial aimed to compare the safety and effectiveness of adding luspatercept to cyclosporine versus cyclosporine alone in adults newly diagnosed with non-severe aplastic anemia (NSAA). The goal was to see if the combination could improve blood cell counts better than the standard drug alone. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept and cyclosporine
What this could lead to: If it had worked, this could have pointed toward a more effective treatment for non-severe aplastic anemia, potentially improving blood cell counts without transfusions.
What could go wrong: The trial was withdrawn before any patients were enrolled, so no results are available. Even if conducted, it was a small early-phase study, and the combination may not have proven safer or more effective than cyclosporine alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.